RED:TA819 - Sacituzumab govitecan for treating
unresectable triple-negative advanced breast cancer after 2 or more therapies. (Decision date - September 2022)
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
